Article in Nanomedicine (London, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.
International journal of molecular sciences · 2022
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
15 authors at 4 institutions in 3 countries.
Hari Krishnareddy RachamallaApplied Biology Division, CSIR-Indian Institute of Chemical Technology, Uppal Road, Hyderabad, Telangana 500007, India.ORCID 0000-0003-0514-4428
Santanu BhattacharyaDepartment of Biochemistry & Molecular Biology, Mayo Clinic College of Medicine & Science, Jacksonville, FL, USA.ORCID 0000-0003-3579-4317
Ajaz AhmadDepartment of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.ORCID 0000-0001-6295-8685
Kathyayani SridharanApplied Biology Division, CSIR-Indian Institute of Chemical Technology, Uppal Road, Hyderabad, Telangana 500007, India.
Vijay Sagar MadamsettyDepartment of Biochemistry & Molecular Biology, Mayo Clinic College of Medicine & Science, Jacksonville, FL, USA.ORCID 0000-0001-9883-190X
Sujan Kumar MondalDepartment of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.
Enfeng WangDepartment of Biochemistry & Molecular Biology, Mayo Clinic College of Medicine & Science, Jacksonville, FL, USA.
Shamit K DuttaDepartment of Biochemistry & Molecular Biology, Mayo Clinic College of Medicine & Science, Jacksonville, FL, USA.
Basit L JanDepartment of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.
Sudhakar JinkaApplied Biology Division, CSIR-Indian Institute of Chemical Technology, Uppal Road, Hyderabad, Telangana 500007, India.
Madan Mohan Chandra Sekhar JaggarapuApplied Biology Division, CSIR-Indian Institute of Chemical Technology, Uppal Road, Hyderabad, Telangana 500007, India.
Venu YakatiApplied Biology Division, CSIR-Indian Institute of Chemical Technology, Uppal Road, Hyderabad, Telangana 500007, India.
Debabrata MukhopadhyayDepartment of Biochemistry & Molecular Biology, Mayo Clinic College of Medicine & Science, Jacksonville, FL, USA.ORCID 0000-0003-1858-5054
Khalid M AlkharfyDepartment of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.ORCID 0000-0002-9118-5076
Rajkumar BanerjeeApplied Biology Division, CSIR-Indian Institute of Chemical Technology, Uppal Road, Hyderabad, Telangana 500007, India.ORCID 0000-0003-2336-6294
Indian Institute of Chemical Technology · INJacksonville College · USKing Saud University · SAUniversity of Pittsburgh · US
Funding
Targeting Pancreatic Cancer Using Peptide Chemistry: From Bench to BedsideR01CA150190 · NCI · MAYO CLINIC ROCHESTER · PI MIERKE, DALE F, MUKHOPADHYAY, DEBABRATA · 2010 to 2021
$5.7M
Regulatory Pathways and Role of VPF/VEGF in Renal CancerR01CA078383 · NCI · MAYO CLINIC ROCHESTER · PI MUKHOPADHYAY, DEBABRATA · 2004 to 2019
$4.5M
REGULATORY PATHWAYS AND ROLE OF VPF/VEGF IN RENAL CANCERR29CA078383 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI MUKHOPADHYAY, DEBABRATA · 1998 to 2002
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Enriched pharmacokinetic behavior and antitumor efficacy of thymoquinone by liposomal delivery. · full record | OpenQuestion